{"groups":[{"description":"Participants were treated with irinotecan liposome injection 50 milligram per square meter (mg/m\\^2) followed by oxaliplatin 60 mg/m\\^2, followed by leucovorin (LV) 400 mg/m\\^2 and then 5-fluorouracil (FU) 2400 mg/m\\^2 intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression, death, unacceptable study treatment-related toxicity or withdrawal of consent.","id":"FG000","title":"NALIRIFOX"},{"description":"Participants were treated with nab-paclitaxel 125 mg/m\\^2 followed by gemcitabine 1000 mg/m\\^2 IV on Days 1, 8 and 15 of each 28-day cycle until disease progression, death, unacceptable study treatment-related toxicity or withdrawal of consent.","id":"FG001","title":"Nab-paclitaxel+Gemcitabine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"338"},{"groupId":"FG001","numSubjects":"351"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"20"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"5"}],"type":"Progressive disease per RECIST"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}],"type":"Switched to commercial drug supply"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Transition to expanded access program"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant randomized in error"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Does Not Meet Entry Criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"383"},{"groupId":"FG001","numSubjects":"387"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"370"},{"groupId":"FG001","numSubjects":"379"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"383"},{"groupId":"FG001","numSubjects":"387"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This study consisted of a screening period (up to 28 days), treatment period (28-day cycles of treatment until radiologically determined disease progression per response evaluation criteria in solid tumors \\[RECIST 1.1\\]), unacceptable study medication related toxicity or withdrawal from study treatment followed by survival follow-up (until death or study closure, whichever occurred first). A total of 770 participants were randomized in 1:1 ratio using an interactive web response system (IWRS).","recruitmentDetails":"This Phase 3, open-label study was conducted in participants with metastatic adenocarcinoma of the pancreas at 187 investigational sites in 18 countries (Australia, Brazil, Canada, Israel, Republic of Korea, United States, Austria, Belgium, Czechia, France, Germany, Greece, Hungary, Italy, Portugal, Spain, United Kingdom, and Russia) between 11 February 2020 and 18 February 2025."}